Dermatology Center for Outcomes Research and Safety (DCORS)

DCORS Mission

  • DCORS mission is to provide infrastructure for sponsored clinical trials, investigator-initiated studies, as well as quality and safety improvement measurement.  
  • DCORS misision is also to provide an environment that fosters new discovery and education in research.
  • Our goal is to facilitate the translation of basic science research into practical applications that will benefit patients, as well as investigate “real world” issues related to medical intervention.
  • Additionally, DCORS provides Emory investigators assistance in various aspects of conducting research, including designing protocols and budgets, obtaining IRB approval, patient recruitment, logistics of patient evaluation and data collection, and data analysis.

DCORS Structure

Three components that address our mission:

  • DCORS Clinical Trials Unit
  • Outcomes Research and Investigator-initiated Research
  • Measurement for quality improvement and safety

DCORS Clinical Trial Unit

Pruritus Related Clinical Trials: 

Menlo MTI-103:  A Randomized, Double-Blind, Placebo Controlled Study Of The Efficacy, Safety, And Tolerability Of Serlopitant For The Treatment Of Pruritus In Adults And Adolescents With A History Of Atopic Dermatitis 

Inclusion Criteria: 
  • Male or female, age 13 years or older 
  • Pruritus prior to and during the initial screening period 
  • Diagnosis of atopic dermatitis 
  • Judged to be in good health in the investigator's opinion 
Exclusion Criteria: 
  • Prior treatment with study drug or similar drug 
  • Pruritus due to another reason besides atopic dermatitis 
  • Presence of any medical condition or disability that could interfere with study 
  • History of hypersensitivity to serlopitant or any of its components 
  • Currently pregnant or male partner of pregnant female 
  • Females of childbearing potential who are unable or unwilling to use adequate contraception or who are breast feeding 

Celgene CC-10004-PPSO-001:  A Phase 2, Multicenter, Open-Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Recruiting for Group 2 (ages 6 to 11 years, inclusive; weight ≥ 15 kg) 
Inclusion Criteria: 
  • Subjects must satisfy all of the following criteria to be enrolled in the study: 
  1. Male or female subjects 6 to 17 years of age, inclusive, at the time the informed consent document is signed by the legal guardian 
  2. Group 1 Only: ages 12 to 17 years, inclusive, and weighs ≥ 35 kg 
  3. Group 2 Only: ages 6 to 11 years, inclusive, and weighs ≥ 15 kg 
  4. Subject is able to swallow the apremilast tablet 
  5. Able to sign an assent with a legal guardian who can understand and voluntarily sign an informed consent 
  6. Able to adhere to the study visit schedule and other protocol requirements 
  7. Must agree to withhold vaccinations during the first 2 weeks of dosing. Inactivated vaccines will be allowed during the extension treatment period 
  8. Diagnosis of chronic plaque psoriasis for at least 6 months prior to Screening 
  9. Have moderate to severe plaque psoriasis at Screening and Baseline as defined by additional criteria